A prospective, cross sectional study evaluating the subjective symptoms and objective ocular surface signs in patients with benign essential blepharospasm both before and after botulinum toxin type-A treatment
Latest Information Update: 03 Dec 2020
Price :
$35 *
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Blepharospasm
- Focus Therapeutic Use
- 03 Dec 2020 New trial record